SCHEMBL29301792

SCHEMBL29301792

Cc1ccc(-c2cc(C(C)(C)C)no2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 10/20 0.54
RAB9A P51151 10/20 0.54
CASP3 P42574 1/20 0.54
SENP8 Q96LD8 1/20 0.54
SENP7 Q9BQF6 1/20 0.54
SENP6 Q9GZR1 1/20 0.54
TP53 P04637 5/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
HPGD P15428 2/20 0.45
ALDH1A1 P00352 1/20 0.45
TSHR P16473 1/20 0.45
LMNA P02545 2/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
MAPT P10636 3/20 0.43
POLB P06746 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
S1PR1 P21453 2/20 0.41
HSD17B10 Q99714 1/20 0.40
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24636027 0.85 KIF11 (0.46) NPC1RAB9ACASP3SENP8SENP7
SCHEMBL12548113 0.85 NPC1 (0.51) NPC1RAB9ATP53SMN1; SMN2HPGD
SCHEMBL12245198 0.85 PTGS2 (0.48) NPC1RAB9ACASP3SENP8SENP7
SCHEMBL31375610 0.85 NPC1 (0.51) NPC1RAB9ACASP3SENP8SENP7
SCHEMBL17788471 0.85 ALDH1A1 (0.53) NPC1RAB9ACASP3SENP8SENP7
SCHEMBL9607554 0.85 RAB9A (0.55) NPC1RAB9ACASP3SENP8SENP7
SCHEMBL2270503 0.78 NPC1 (0.59) NPC1RAB9ACASP3SENP8SENP7
SCHEMBL25557805 0.78 RAB9A (0.69) NPC1RAB9ACASP3SENP8SENP7
Ammonia Solution, Strong SCHEMBL28862474 0.76 NPC1 (0.58) NPC1RAB9ACASP3SENP8SENP7
SCHEMBL19598795 0.76 RAB9A (0.86) NPC1RAB9ACASP3SENP8SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME SLC10A1, NR1H4, SLC10A2 NPC1 295/4885RAB9A 2422/4885CASP3 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.